Philadelphia, PA, United States of America

Charlly Kao

This inventor holds 12 USPTO granted patents and 10 published patent applications, plus 4 CIPO patents and 9 EPO patents. Top assignees: The Children's Hospital of Philadelphia, Arctic Therapeutics Hf. Active years: 2018-2026.

USPTO Granted Patents = 12 (Patent Applications = 10)

% Patents Active = 100.0

CIPO Patents = 4 (Patent Applications = 7)

EPO Patents = 9 (Patent Applications = 17)

Average Co-Inventor Count = 2.5

ph-index = 2

Forward Citations = 16(Granted Patents)

Company Filing History:

11 out of 299

The Children's Hospital of Philadelphia

patents

1 out of 1

Arctic Therapeutics Hf

patent

Years Active: 2018-2026

Loading Chart...

12 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12582637 - Topical formulation for intradermal application and uses thereof (2026-03-24),

2. 12365946 - Compositions and methods for the diagnosis and treatment of lymphatic system disorders (2025-07-22),

3. 12121514 - Nonselective metabotropic glutamate receptor activators for treatment of attention deficit disorder and 22Q syndrome (2024-10-22),

4. 11806340 - Methods of diagnosing and treating conduct disorder (2023-11-07),

5. 11298347 - Methods of diagnosing and treating Tourette syndrome (2022-04-12),

6. 11219617 - Methods of diagnosing and treating autism (2022-01-11),

7. 11179378 - Methods of diagnosing and treating conduct disorder (2021-11-23),

8. 11173153 - Methods of diagnosing and treating anxiety disorder (2021-11-16),

9. 10918632 - Nonselective metabotropic glutamate receptor activators for treatment of anorexia nervosa and binge eating disorder (2021-02-16),

10. 10869861 - Nonselective metabotropic glutamate receptor activators for treatment of attention deficit disorder and 22Q syndrome (2020-12-22),

11. 10407725 - Methods of treating autoimmune conditions in patients with genetic variations in DcR3 or in a DcR3 network gene (2019-09-10),

12. 9884057 - Nonselective metabotropic glutamate receptor activators for treatment of attention deficit disorder and 22Q syndrome (2018-02-06),

Title: Inventor Charlly Kao: Pioneering Advances in Neuropharmacology

Introduction: Charlly Kao is an esteemed inventor based in Philadelphia, PA, who has made significant contributions to the field of neuropharmacology. With a remarkable portfolio of 10 patents, Kao has been at the forefront of developing innovative treatments that address complex neurological disorders.

Latest Patents: Among her latest patents are groundbreaking methods for treating attention deficit hyperactivity disorder (ADHD) and 22q deletion and/or duplication syndrome. One of her notable inventions involves a nonselective activator of metabotropic glutamate receptors, such as fasoracetam, to assist individuals with genetic alterations in metabotropic glutamate receptor (mGluR) network genes. Additionally, Kao has developed methods for diagnosing and treating conduct disorder, focusing on genetic assessments and utilizing nonspecific activators of mGluRs, like fasoracetam.

Career Highlights: Charlly Kao works at The Children’s Hospital of Philadelphia, where she has dedicated her career to enhancing the understanding of neurodevelopmental disorders. Her research has led to promising therapeutic strategies that can significantly improve patient outcomes.

Collaborations: Kao has collaborated with notable colleagues, including Hakon Hakonarson and Christopher Cardinale. Together, they have worked on pioneering research that bridges the gap between genetics and innovative treatment modalities in neuropharmacology.

Conclusion: With a strong focus on addressing critical issues related to ADHD and conduct disorders, Charlly Kao continues to push the boundaries of medical science. Her innovative contributions not only reflect her dedication to advancing healthcare but also inspire future generations of inventors in the field of neuropharmacology.